Last reviewed · How we verify
Oral L-arginine aspartate administration
Oral L-arginine aspartate administration is a Amino acid supplement / Nitric oxide donor Small molecule drug developed by Ukrainian Medical Stomatological Academy. It is currently in Phase 3 development for Erectile dysfunction, Cardiovascular insufficiency, Endothelial dysfunction. Also known as: Oral supplementation with Tivortin® Aspartate (Yuria-Pharm, Ukraine).
L-arginine aspartate is a nitric oxide precursor that enhances endothelial function and vascular reactivity through increased NO production.
L-arginine aspartate is a nitric oxide precursor that enhances endothelial function and vascular reactivity through increased NO production. Used for Erectile dysfunction, Cardiovascular insufficiency, Endothelial dysfunction.
At a glance
| Generic name | Oral L-arginine aspartate administration |
|---|---|
| Also known as | Oral supplementation with Tivortin® Aspartate (Yuria-Pharm, Ukraine) |
| Sponsor | Ukrainian Medical Stomatological Academy |
| Drug class | Amino acid supplement / Nitric oxide donor |
| Target | Nitric oxide synthase (NOS) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
L-arginine serves as a substrate for nitric oxide synthase (NOS), promoting the synthesis of nitric oxide, a critical signaling molecule that regulates vasodilation, blood flow, and endothelial function. The aspartate salt formulation may improve bioavailability and absorption. This mechanism supports improved cardiovascular hemodynamics and tissue perfusion.
Approved indications
- Erectile dysfunction
- Cardiovascular insufficiency
- Endothelial dysfunction
Common side effects
- Gastrointestinal disturbance
- Nausea
- Diarrhea
- Abdominal discomfort
Key clinical trials
- : Vascular Function in Health and Disease (PHASE1)
- Supplementation With L-ornithine But Not L-arginine Increases Density of CD68+ and CD163+ Macrophages in Periodontitis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oral L-arginine aspartate administration CI brief — competitive landscape report
- Oral L-arginine aspartate administration updates RSS · CI watch RSS
- Ukrainian Medical Stomatological Academy portfolio CI
Frequently asked questions about Oral L-arginine aspartate administration
What is Oral L-arginine aspartate administration?
How does Oral L-arginine aspartate administration work?
What is Oral L-arginine aspartate administration used for?
Who makes Oral L-arginine aspartate administration?
Is Oral L-arginine aspartate administration also known as anything else?
What drug class is Oral L-arginine aspartate administration in?
What development phase is Oral L-arginine aspartate administration in?
What are the side effects of Oral L-arginine aspartate administration?
What does Oral L-arginine aspartate administration target?
Related
- Drug class: All Amino acid supplement / Nitric oxide donor drugs
- Target: All drugs targeting Nitric oxide synthase (NOS)
- Manufacturer: Ukrainian Medical Stomatological Academy — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Erectile dysfunction
- Indication: Drugs for Cardiovascular insufficiency
- Indication: Drugs for Endothelial dysfunction
- Also known as: Oral supplementation with Tivortin® Aspartate (Yuria-Pharm, Ukraine)
- Compare: Oral L-arginine aspartate administration vs similar drugs
- Pricing: Oral L-arginine aspartate administration cost, discount & access